Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $313000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 99.63% to $313000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $313000.0 through Dec 2025, down 99.63% year-over-year, with the annual reading at $313000.0 for FY2025, 99.63% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $313000.0 at Theravance Biopharma, roughly flat from $313000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $83.7 million in Q4 2024, with the low at $313000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $21.5 million, with a median of $4.9 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 2301.72% in 2022, then crashed 99.63% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $75.0 million in 2021, then increased by 1.3% to $76.0 million in 2022, then increased by 4.57% to $79.5 million in 2023, then grew by 5.32% to $83.7 million in 2024, then plummeted by 99.63% to $313000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $313000.0, $313000.0, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.